We have placed cookies on your computer to help make this website better. We use a Matomo Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by Matomo (e.g. deny use/opt-out).

Ok, continue to the website

Jan Adams Chief Scientific Officer | Leadership | About us | Grünenthal Group
;

Jan Adams

Member of the Corporate Executive Board, Chief Scientific Officer (CSO)

Jan Adams, Chief Scientific Officer (CSO) Grünenthal

“Our R&D organisation is the driving force behind our pipeline of highly innovative assets that will deliver towards our vision of a world free of pain.”

Jan Adams

Chief Scientific Officer, Grünenthal

Always driven to improve patients’ lives, Jan Adams has built up more than 15 years of experience in healthcare and biopharmaceuticals.

Jan significantly contributed to working out our concise therapeutic area strategy and led the design and implementation of a future-proof R&D operating model that can successfully execute our strategy – flexible and modality-agnostic while leveraging a strong global network.

Jan joined Grünenthal in July 2017 as Head Corporate Strategy and Portfolio Management, working at the interface between strategy, research, development and commercial. Prior to joining Grünenthal, he served in roles with increasing levels of responsibility at Novartis and Takeda, as well as within McKinsey & Company’s global Pharmaceutical and Medical Products practice.

Jan Adams at a glance


Nationality: German

Year of birth: 1977

Education:  Medical Doctor (MD) at Medical Schools in Kiel, Frankfurt and Sidney; Doctoral Thesis at Goethe University Frankfurt

Family status: Married, two children

Leisure time:  My 2 daughters, traveling, hiking


Career highlights

Since 2020: Member of the Corporate Executive Board and Chief Scientific Officer, Grünenthal

2019: Deputy/Acting Chief Scientific Officer, Grünenthal

2017 – 2019: Senior Vice President & Head Corporate Strategy and Portfolio Management, Grünenthal

2016-2017: Vice President & Head R&D Strategic Management and Planning, Takeda Pharmaceuticals Inc.

2008-2016: Associate Principal, McKinsey & Company

2005-2007: Project Leader Cardiovascular and Hemostaseology, Clinical Development and Medical Affairs, Novartis Pharma

2004 – 2005: Resident at Hannover Medical School (MHH)